Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.

Journal of hepatology - 1 Dec 2009

Sanchez Mayra J, Buti Maria, Homs Maria, Palacios Andres, Rodriguez-Frias Francisco, Esteban Rafael

Abstract excerpt

BACKGROUNDS/AIMS: Hepatitis B virus (HBV) reactivation following treatment with rituximab has been reported in patients with either HBsAg-positive, or HBsAg-negative and anti-HBc positive infection. Patients with severe reactivation often have a fatal outcome despite treatment with lamivudine. The use of entecavir has not been reported in patients with severe HBV reactivation. METHODS: We present a case of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Guanine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis B

Share to Hepatitis B Surface Antigens

Share to Immunosuppressive Agents

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Rituximab

Share to Vidarabine

Source

Identifiers

PMID: 19836097
DOI: 10.1016/j.jhep.2009.07.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.PMID 19836097Read ↗

Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.Semantic proximity Read ↗

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.Semantic proximity Read ↗

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.Semantic proximity Read ↗

Hepatitis C Virus-Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment.Semantic proximity Read ↗

Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.Semantic proximity Read ↗

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy.Semantic proximity Read ↗

Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.Semantic proximity Read ↗

Use of entecavir for the treatment of complex forms of hepatitis B.Semantic proximity Read ↗

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.Semantic proximity Read ↗

Risk of hepatitis B virus reactivation in B-cell malignancies treated with BTK inhibitorsSemantic proximity Read ↗

Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection.Semantic proximity Read ↗

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.